To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to
patients with early and moderate Atrophic Age Related Macular Degeneration.
To evaluate whether or not zeaxanthin supplementation raises macular pigment optical density
(MPOD). Previous research has shown MPOD to mirror visual benefits for patients with age
related atrophic macular degeneration (AMD) having visual symptoms (decreased visual acuity,
contrast sensitivity, photostress glare recovery and National Eye Institute Visual Function
Questionnaire 25 scores), but lower risk National Eye Institute (NEI) / Age Related Eye
Disease Study (AREDS) characteristics.
- diagnosis of atrophic AMD (ICD9 362.51) by stereo bio-ophthalmoscopy and at least one
vision degrading visual-psychophysical abnormality associated with AMD in one or both
- clear non-lenticular ocular media (cornea, aqueous and vitreous)
- free of advanced glaucoma and diabetes or any other ocular or systemic disease that
could affect central or parafoveal macula visual function
- high risk retinal characteristics for advanced AMD or advanced AMD for which existing
medical / surgical options are available
- presence of ophthalmologically significant active exudative, AMD pathology by
fluorescein angiography but also a single large drusen, >15, multiple intermediate
drusen, parafoveal geographic atrophy or loss of vision in one eye due to advanced
- recent (within 6 months) cataract or retinal surgery
- taking photosensitizing drugs such as phenothiazines and chloroquine
- having taken lutein or zeaxanthin supplements within the past six months.